Haixin Biological

Shanghai Haixin Biological Technology is a Chinese biotechnology company specializing in the development of autologous cell therapies for oncology. The company's flagship product, APDC (Antigen-sensitized Peripheral Blood Dendritic Cells), is a dendritic cell-based vaccine currently in Phase 3 clinical trials for the treatment of colorectal cancer. Established as a joint venture involving the Shanghai Haixin Group and academic institutions, it was one of the first companies in China to receive approval for a cellular immunotherapy clinical trial. Haixin Biological's platform focuses on the isolation and ex vivo activation of immune cells to recognize specific tumor markers. The company continues to play a significant role in the landscape of Chinese cancer immunotherapy research, leveraging its early-mover advantage in the regulatory space. As a subsidiary of a publicly traded group, it maintains a focus on bringing domestic cell therapy innovations to the commercial market.